Cantor FrizA$$kick Cantor when he was a buyer at $1.70, while telling BNN the sp is not worth 0.50?? Because that wasn't exactly a buy in, but a Short. Exclaiming no Metatastic? testing?? How does one get phase three approval without having a commercially viable compound that uniform throughout the process, and have consistent product that is being used with trials to measurably accountable to approve. Blame the monkeys whom have been shorting, Cantor? Blame our great partners whom are being taken over by larger fish, blame distributors whom need time to consider the costs of Disruptive technology. PLI is one in a few companies that arte changing the way compounds, and how new methods are going to change the landscape. Thomvest simply protected its interest from Cantor, and other third party larger fishes from doing so themselves. INK some new research trials and get on with business.